FDA approves Retatrutide this year?
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’…
As of 12 September 2026, the market prices "Yes" at 6% implied probability (+2.2pp over the last 24h). The biggest 24h move is "No", from 97% to 94%. The event has traded $582.9K in total ($50 in the last 24h) with $2.4K of liquidity across 1 market. Trading is due to close on 31 December 2026.
Chart, demo trading & order book
Test this market with $10,000 virtual funds
Free account: paper trade on the real order book, follow whale moves, stack airdrop points.
Start freeAlready have an account? Sign in
Holders and activity
Markets and probabilities
1 marketsThe percentage is the implied probability of the outcome, between 0% and 100%. For mutually-exclusive markets the sum trends to 100% (no vig). The ▲/▼ arrow shows the change over the selected window (1h/24h/7d/30d) in percentage points (pp). Click a market to see its top holders (with average entry price and position change) and the latest trades.